Optimizing Care for Cancer Survivors With Depression: Project 3

Summary

The purpose of this research study is to evaluate different depression treatment approaches among cancer survivors. A cancer survivor is defined as anyone who is living and has been diagnosed with cancer. Participants will be randomly assigned to either receive a mobile app for depression treatment, called "Moodivate", or to receive telehealth depression treatment sessions. Approximately 2/3 of participants enrolled will receive the mobile app and the remaining 1/3 will receive depression treatment via telehealth. Participants that receive Moodivate may later be assigned to also receive depression treatment via telehealth based their response to the Moodivate app. Participants will be asked to either use the Moodivate app and/or receive depression treatment via telehealth for a period of 10 weeks. All participants will be asked to electronic questionnaire measures throughout the study period. Questionnaires will assess symptoms of depression, as well as general experiences using Moodivate and participating in this trial. Participation in this study will take about 24 weeks. Participation in this study may help improve options for emotional wellness for cancer survivors. The greatest risks of this study include frustration, worsening of emotional distress, data breach, and/or loss of confidentiality.

Eligibility

Inclusion Criteria:

* age 18+
* cancer survivor
* current elevated depressive symptoms defined per ASCO as a PHQ-9 score ≥ 8
* not currently receiving psychosocial depression treatment
* have the ability to complete treatment via telehealth and use Moodivate
* have a valid e-mail address or text message access (for assessments)
* English fluency

Exclusion Criteria:

\- Current suicidal ideation at final eligibility screening (PHQ-9 item 9 ≥1)

Conditions2

Locations1 site

Browse More Trials